2893809-51-1
Chemical Structure
BBO-8520
- CAS No.: 2893809-51-1
- Formula:C35H33F6N7O2S
- Molecular Weight:729.74
InChIKey: RIVFEDYNLHJKEZ-VHJOERAISA-N
SMILES: FC1=[C@](C(C(F)(F)F)=CC2=C(N=C(N=C21)OC[C@@]34CCCN3C[C@@H](C4)F)N5[C@H](CN([C@@H](C5)C)C(C=C)=O)C)[C@]6=CC=C(F)C7=C6C(C#N)=C(N)S7
Biological Activity: BBO-8520 is a direct small molecule covalent inhibitor targeting KRAS G12C with high oral availability. BBO-8520 has the characteristics of KRAS G12C (OFF) inhibitor and the function of blocking KRASG12C (ON) signal. BBO-8520 inhibits cell proliferation by inhibiting KRAS G12C (ON) by binding GTP protein. BBO-8520 can block RAS-RAF1 interaction and return KRAS G12C to the inactive (OFF) state. BBO-8520 can be used for the research of cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BBO-8520 | 99.36% | BBO-8520 is a direct small molecule covalent inhibitor targeting KRAS G12C with high oral availability. BBO-8520 has the characteristics of KRAS G12C (OFF) inhibitor and the function of blocking KRASG12C (ON) signal. BBO-8520 inhibits cell proliferation by inhibiting KRAS G12C (ON) by binding GTP protein. BBO-8520 can block RAS-RAF1 interaction and return KRAS G12C to the inactive (OFF) state. BBO-8520 can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-158107A(4R)-BBO-8520 -
Similarity Score 0.80
HY-181420(S,R,S)-BBO-11818 -
Similarity Score 0.80
HY-181420ABBO-11818 -
Similarity Score 0.68
HY-164749K-Ras-IN-4 -
Similarity Score 0.67
HY-164350KRAS inhibitor-27 -
Similarity Score 0.65
HY-171581KRAS G12D-IN-27 -
Similarity Score 0.63
HY-115880AKRAS G12D inhibitor 3 TFA -
Similarity Score 0.61
HY-162439pan-KRAS-IN-6 -
Similarity Score 0.60
HY-173637AZD0022 -
Explore the MedChemAI to find more analogs
References
- [1]. Maciag A E, et al. Abstract ND07: BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding[J]. Cancer Research, 2024, 84(7_Supplement): ND07-ND07.
- [2]. Caughey B A, Strickler J H. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies[J]. Drugs, 2024, 84(1): 27-44.
